Citius Pharmaceuticals to Present at the H.C. Wainwright Global Investment Conference on May 24, 2022
Citius Pharmaceuticals (CTXR), a late-stage biopharmaceutical company, announced its presentation at the H.C. Wainwright Global Investment Conference scheduled for May 24, 2022. CEO Leonard Mazur will discuss recent business developments and milestones. The event will take place virtually and at the Fontainebleau Miami Beach Hotel. Registrants can access a live webcast and schedule 1-on-1 meetings with management. Citius is focused on innovative critical care products, including Mino-Lok® and I/ONTAK, addressing serious medical conditions.
- None.
- None.
CRANFORD, N.J., May 18, 2022 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company developing and commercializing first-in-class critical care products, today announced that it will present at the H.C. Wainwright Global Investment Conference being held May 23-26, 2022. Leonard Mazur, Chairman and CEO of Citius, will discuss the Company's recent business developments and upcoming milestones.
H.C. Wainwright Global Investor Conference | |
Presentation date and time: | Tuesday, May 24, 2022 at 11:00 a.m. ET |
Location: | Virtual and at the Fontainebleau Miami Beach Hotel, Miami Beach, Florida |
Registration: | Visit the conference website for in-person or virtual registration |
Live webcast: | Register here to view |
Webcast replay: | Available for 90 days |
Interested parties may schedule 1-on-1 meetings with Citius management by registering through the event platform or contacting the Company's investor relations team.
About Citius Pharmaceuticals, Inc.
Citius is a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on oncology, anti-infectives in adjunct cancer care, unique prescription products, and stem cell therapies. The Company has two late-stage product candidates, Mino-Lok®, an antibiotic lock solution for the treatment of patients with catheter-related bloodstream infections (CRBSIs), which is currently enrolling patients in a Phase 3 Pivotal superiority trial, and I/ONTAK (E7777), a novel IL-2R immunotherapy for an initial indication in cutaneous T-cell lymphoma (CTCL), which has completed enrollment in its Pivotal Phase 3 trial. Mino-Lok® was granted Fast Track designation by the U.S. Food and Drug Administration (FDA). I/ONTAK has received orphan drug designation by the FDA for the treatment of CTCL and peripheral T-cell lymphoma (PTCL). Through its subsidiary, NoveCite, Inc., Citius is developing a novel proprietary mesenchymal stem cell treatment derived from induced pluripotent stem cells (iPSCs) for acute respiratory conditions, with a near-term focus on acute respiratory distress syndrome (ARDS) associated with COVID-19. For more information, please visit www.citiuspharma.com.
Investor Relations for Citius Pharmaceuticals:
Ilanit Allen
Vice President, Investor Relations and Corporate Communications
T: 908-967-6677 x113
E: ir@citiuspharma.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/citius-pharmaceuticals-to-present-at-the-hc-wainwright-global-investment-conference-on-may-24-2022-301549451.html
SOURCE Citius Pharmaceuticals, Inc.
FAQ
When will Citius Pharmaceuticals present at the H.C. Wainwright Global Investment Conference?
Where will the H.C. Wainwright Global Investment Conference be held?
How can I register for the H.C. Wainwright Global Investment Conference?
What is Citius Pharmaceuticals focusing on during the conference?
What products are Citius Pharmaceuticals developing?
